Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables RefundsShares Issued
Ratios

Ligand Pharmaceuticals (LGND) Loans and Notes Receivables: 2015-2018

Historic Loans and Notes Receivables for Ligand Pharmaceuticals (LGND) over the last 3 years, with Mar 2018 value amounting to $3.9 million.

  • Ligand Pharmaceuticals' Loans and Notes Receivables was N/A to $3.9 million in Q1 2018 from the same period last year, while for Mar 2018 it was $3.9 million, marking a year-over-year change of. This contributed to the annual value of $3.9 million for FY2017, which is 20.89% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Loans and Notes Receivables stood at $3.9 million for Q1 2018, which was down 0.00% from $3.9 million recorded in Q4 2017.
  • Over the past 5 years, Ligand Pharmaceuticals' Loans and Notes Receivables peaked at $5.5 million during Q2 2015, and registered a low of $3.0 million during Q3 2017.
  • In the last 3 years, Ligand Pharmaceuticals' Loans and Notes Receivables had a median value of $3.2 million in 2017 and averaged $3.5 million.
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Loans and Notes Receivables slumped by 42.18% in 2016, and later increased by 20.89% in 2017.
  • Over the past 4 years, Ligand Pharmaceuticals' Loans and Notes Receivables (Quarterly) stood at $4.8 million in 2015, then slumped by 32.94% to $3.2 million in 2016, then climbed by 20.89% to $3.9 million in 2017, then reached $3.9 million in 2018.
  • Its Loans and Notes Receivables was $3.9 million in Q1 2018, compared to $3.9 million in Q4 2017 and $3.0 million in Q3 2017.